Extended-release Naltrexone for Alcohol and Opioid Dependence: A Meta-Analysis of Healthcare Utilization Studies

Scott E. Hadland, MD, MPH, John R. Knight, MD, and Sion K. Harris, PhD1
Marijuana policy is rapidly evolving in the United States and elsewhere, with cannabis sales fully legalized and regulated in some jurisdictions and use of the drug for medicinal purposes permitted in many others. Amidst this political change, patients and families are increasingly asking whether cannabis and its derivatives may have therapeutic utility for a number of conditions, including developmental and behavioral disorders in children and adolescents. This review examines the epidemiology of cannabis use among children and adolescents, including those with developmental and behavioral diagnoses. It then outlines the increasingly well-recognized neurocognitive changes shown to occur in adolescents who use cannabis regularly, highlighting the unique susceptibility of the developing adolescent brain and describing the role of the endocannabinoid system in normal neurodevelopment. The review then discusses some of the proposed uses of cannabis in developmental and behavioral conditions, including attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Throughout, the review outlines gaps in current knowledge and highlights directions for future research, especially in light of a dearth of studies specifically examining neurocognitive and psychiatric outcomes among children and adolescents with developmental and behavioral concerns exposed to cannabis
For full article


Whilst OTC opioid issue in this article refers to the US current issue, the Australian context is beginning to catch up!

Opioid Abuse in Chronic Pain — Misconceptions and Mitigation Strategies

Nora D. Volkow, M.D., and A. Thomas McLellan, Ph.D.: N Engl J Med 2016; 374:1253-1263  March 31, 2016DOI: 10.1056/NEJMra1507771
However, two major facts can no longer be questioned. First, opioid analgesics are widely diverted and improperly used, and the widespread use of the drugs has resulted in a national epidemic of opioid overdose deaths and addictions. More than a third (37%) of the 44,000 drug-overdose deaths that were reported in 2013 (the most recent year for which estimates are available) were attributable to pharmaceutical opioids; heroin accounted for an additional 19%. At the same time, there has been a parallel increase in the rate of opioid addiction, affecting approximately 2.5 million adults in 2014. 9 Second, the major source of diverted opioids is physician prescriptions.10,  11 For these reasons, physicians and medical associations have begun questioning prescribing practices for opioids, particularly as they relate to the management of chronic pain. Moreover, many physicians admit that they are not confident about how to prescribe opioids safely, 12 how to detect abuse or emerging addiction, or even how to discuss these issues with their patients. 13
Read Complete Paper

You can view the Dalgarno Institutes AOD Policy by clicking on the links below


WHO Paper Cannabis & Medical Use Dr B Madras - 2015

Cannabis Liberalization & Cross-Natoinal THC Use - 38 Counties
Alcohol and other drug Policy proposal - "A community safety, health and care approach"
Marijuana Use Detrimental to Youth - American College of Pediatricians 2015
Medical Marijuana Ruse - September 2015 DFA
Legalizing marijuana for medical purposes will increase risk
We need policy consistency!
Normalisation of drug use
30 Years of Harm Minimisation

Monitoring International Drug Policy

Useful Material
Statement from WFAD on the Global Commission on Drug Policys - Report September 14
Press Release Drug Policy Futures 13th March 2014

Monitoring Government Policy & Strategy